IRCT201105236568N1CompletedPhase 2
Effects of topical interferon Gamma 1b in the treatment of uveitic cystoid macular edema
Conditions
Trial Snapshot
- Phase
- Phase 2
- Status
- Completed
- Enrollment
- 10
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- 18 years to 60 years (—)
- Sex
- All
Inclusion Criteria
- •(to have medial, posterior or pan-uveitis at least 3 months before the participation in the study together with macular cystoid edema secondary to uveitis in at least one eye; to have visual acuity equal or greater than 20/200; to be 18 to 60 year-old; to have a central macular thickness greater than 250 micrometers)
- •Exclusion criteria: (pregnancy or breast feeding; occurrence of intolerable adverse effects; to have a history of herpetic kerititis and multiple sclerosis; to have an active infection which needs an urgent treatment; history of chronic or recurrent infections)
Exclusion Criteria
- Not provided
Investigators
Similar Trials
Completed
Phase 3
Clinical trial for evaluation of the effect of topical interferon a2b as a complementary treatment of macular edema of patients with diabetic retinopathy compared with placebodiabetic retinopathy.Diabetic retinopathyIRCT2016081529370N1Vice chancellor for research of Shiraz University of Medical Sciences50
Completed
Phase 2
The efficacy of topical interferon alpha-2b in pterygiumpterygium.Pterygium of eyeH11.0IRCT20190806044463N1Bagheiat-allah University of Medical Sciences18
Active, not recruiting
Not Applicable
A phase II study about interferon gamma 1b to therapy the steroid-refractory bronchiolitis obliterans after allogenic stem cell therapysteroid-refractory bronchiolitis obliteransMedDRA version: 13.1Level: PTClassification code 10029888Term: Obliterative bronchiolitisSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2010-022467-36-DEFreistaat Bayern
Recruiting
Phase 3
Efficacy and safety of Interferon beta-1-a in mild to moderate COVID-19IRCT20120703010178N25Shahid Beheshti University of Medical Sciences100
Recruiting
Phase 3
ReciGen for treatment of Covid-19Covid 19.COVID-19, virus identifiedU07.1IRCT20150914024017N1Tehran University of Medical Sciences40
